Allschwil, Switzerland

Michel Burcklen

USPTO Granted Patents = 3 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Michel Burcklen: Innovator in Multiple Sclerosis Treatment

Introduction

Michel Burcklen is a notable inventor based in Allschwil, Switzerland. He has made significant contributions to the field of medicine, particularly in the treatment of multiple sclerosis. With a total of 3 patents, Burcklen's work focuses on innovative methods that aim to improve patient outcomes.

Latest Patents

Burcklen's latest patents revolve around methods of treating multiple sclerosis. The disclosures relate to various pharmaceutical products containing ponesimod. These patents include instructions for the use of ponesimod, methods for selling a drug product containing ponesimod, and strategies for reducing clinical management events before or during treatment of multiple sclerosis. His work is crucial in advancing therapeutic options for patients suffering from this challenging condition.

Career Highlights

Throughout his career, Michel Burcklen has been associated with Vanda Pharmaceuticals Inc., where he has played a pivotal role in research and development. His expertise in the pharmaceutical field has allowed him to contribute to groundbreaking treatments that address unmet medical needs.

Collaborations

Burcklen has collaborated with several talented professionals, including Allitia DiBernardo and Tatiana Sidorenko. These partnerships have fostered an environment of innovation and creativity, leading to advancements in the treatment of multiple sclerosis.

Conclusion

In summary, Michel Burcklen is a distinguished inventor whose work in the treatment of multiple sclerosis has the potential to transform patient care. His patents and collaborations reflect a commitment to improving therapeutic options in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…